Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Minutes of the Monetary Policy Meeting held on 13 February 2018

At the Monetary Policy Meeting on 13 February 2018, the Executive Board of the Riksbank decided to hold the repo rate unchanged at –0.50 per cent. The forecast for the repo rate is unchanged since December and indicates that slow repo rate rises are set to be initiated during the second half of this year. Reinvestments of redemptions and coupon payments in the government bond portfolio will continue until further notice.A majority of the Executive Board supported the picture of the economic outlook and inflation prospects described in the draft Monetary Policy Report. Economic activity

Tokmanni’s Corporate brochure 2017 and Corporate Responsibility Report 2017 published

Tokmanni Group Corporation     Corporate brochure 2017 and Corporate Responsibility Report 2017     23 February 2018 at 10:25 (EET)Tokmanni's Corporate brochure 2017 and Corporate Responsibility Report 2017 have been published on the company website ir.tokmanni.fi/en (in Finnish: ir.tokmanni.fi). The documents are also attached to this release both in English and in Finnish. TOKMANNI GROUP CORPORATION For more information: Joséphine Mickwitz Head of IR and Communicationstel. +358 20 728 6535josephine.mickwitz@tokmanni.fi Tokmanni in brief  Tokmanni is the largest

Press information from AB Volvo’s Election CommitteeEric Elzvik proposed as new Board member of AB Volvo

The Election Committee of AB Volvo proposes that Eric Elzvik, be elected as new Board member at the Annual General Meeting on April 5, 2018. The Election Committee also proposes the re-election of Chairman of the Board Carl-Henric Svanberg, as well as Board members Matti Alahuhta, Eckhard Cordes, James W. Griffith, Martin Lundstedt, Kathryn V. Marinello, Martina Merz, Hanne de Mora, Håkan Samuelsson and Helena Stjernholm. Lars Westerberg has announced that he will not be standing for re-election. The Election Committee further proposes that Deloitte AB be elected as auditors for a period of

IAR Systems enables high-performance machine learning based on latest neural network library from Arm

The leading development toolchain IAR Embedded Workbench supports the neural network library Arm CMSIS-NNUppsala, Sweden—February 23, 2018—IAR Systems®, the future-proof supplier of software tools and services for embedded development, has added support for CMSIS-NN, Arm®’s new neural network kernels. The support is available for developers using the latest version of IAR Embedded Workbench® for Arm. The Arm Cortex® Microcontroller Software Interface Standard (CMSIS) provides a single, scalable interface standard across all Arm Cortex-M® series processor vendors, simplifying software

IAR Systems supports new Arm technology for neural networks and artificial intelligence

Uppsala, Sweden—February 23, 2018—IAR Systems announces that the leading development toolchain IAR Embedded Workbench for Arm now supports Arm®’s new neural network library CMSIS-NN, which is an interface standard reducing the learning curve for developers and reducing the time to market for new devices. Neural networks are a set of self-learning algorithms inspired by the biological neural networks that constitute the human brain. Neural networks are trained through machine learning with software analyzing big data to see patterns, which can be applied in face recognition, self-driving

Citycon’s Annual Review and Sustainability Accounts for 2017 published

CITYCON OYJ      Investor News      23 February 2018 at 10:15 hrsCitycon Oyj’s Annual Review for 2017 has been published today. The Annual Review includes the CEO’s interview and presents a review of the company’s strategy, value creation and property portfolio in a new structured way.In addition, Citycon has published its Sustainability Accounts for 2017 today. During 2017, Citycon updated its sustainability strategy, which is described in more detail in the Sustainability Accounts.The Annual Review and Sustainability Accounts are attached to this release and are also available on the

New patient treatment in the clinical phase 1 study

The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well. The treatment method, called Photodynamic Treatment (PDT), means that the patient is given a light-activated drug that accumulates in the tumor. When the cancer tissue is illuminated using SpectraCures instruments, the medicine is activated and the tumour is eliminated. The

Montebello to distribute Biohit products in Norway

Biohit Oyj Press release, February 23rd, 2018 at 10:00 a.m. local time (EET) Biohit Oyj and Montebello Diagnostics AS have signed an agreement for the distribution of Biohit diagnostic products in Norway. The contract has been signed for three years with a continuation option. Managing Director Mika Søderberg, Montebello Diagnostics AS: “The Biohit product range will significantly strengthen our portfolio of gastrointestinal tract diagnostics. GastroPanel® innovation is welcome to the Norwegian health care to promote safe and cost-effective diagnosis and screening of dyspepsia as well

Atria Plc: Managers' transactions

Atria Oyj - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Kiinteistö Oy ItikanmäkiPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Flink ReijoPosition: Member of the Supervisory Board (2):Person Discharging Managerial Responsibilities In IssuerName: Ritola AhtiPosition: Member of the Supervisory Board (3):Person Discharging Managerial Responsibilities In IssuerName: Sairanen RistoPosition: Member of the Supervisory

SelfieSign is the future

Effortless. Practical. Lazy. In our perpetual search for more convenience, digitalisation had yielded a world of e-this and e-that. Undoubtedly such inventions do make our lives easier. Take mobile signing, for instance. Long gone is the circus of printing, mailing by post, scribbling illegible autographs, scanning and then perhaps emailing, in contract management. Mobile signing – eSigning that works on your phone – has removed wasted time and hassle. We already use biometrics, voice recognition and Facebook authentication for online transaction, but it’s not always necessary. Such user

Epiroc Capital Markets Day on May 30, 2018

Stockholm, Sweden, February 23, 2018: Epiroc AB, the company that the Atlas Copco Group plans to dividend out to shareholders this year, will host its first annual Capital Markets Day on May 30, 2018, in Örebro, Sweden.The purpose of the Capital Markets Day is to present Epiroc and its strategy to investors, analysts and financial media. The event will also provide an update on the process of publicly listing Epiroc on the Nasdaq Stockholm stock exchange, planned for mid-2018, provided that Atlas Copco shareholders approve the proposal at the Annual General Meeting on April 24, 2018.

Year-End Report 2017

2017 – An intense year during which we established the base for an aggressive market expansion!Q4 2017 · Net sales for the period amounted to SEK 0.8 (0.3) million. · Earnings for the period amounted to SEK -19.9 (-11.7) million, which corresponds to earnings per share of SEK -0.86 (-1.27). During the quarter a provision of SEK 2.3 million related to replacements of previous deliveries was made for some of the first commercial projects. · Cash and cash equivalents as at December 31 amounted to SEK 38.5 million. · During the quarter, ChromoGenics invoiced and completed

Year-end report 2017 1 January - 31 December

Climeon AB (publ) releases fourth quarter and full year 2017 reportFinancial development, October - December • Order intake amounted to SEK 12.6 million (0.0)  • Net sales amounted to SEK 11.1 million (2.5) • Operating profit/loss amounted to SEK ‐20.2 million (‐13.3) • Earnings per share amounted to SEK ‐0.48 (‐0.38) • Cash amounted to SEK 204.0 million (51.3) • New share issues provided a total of SEK 224.0 million net • Cash flow from operating activities amounted to SEK ‐22.1 million (‐8.9) Important events, October ‐ December • An order of SEK 12.6 million

YEAR-END REPORT 1 OCTOBER – 31 DECEMBER 2017

Fourth quarter 2017, compared to 2016, Group » Gross order intake amounted to SEK 885,088 (626,306), an increase of 41,3% » Order backlog amounted to SEK 893,014 (325,434), an increase of 174,4% » 38% growth in orders for Episealer® knee implants during the quarter with 36 (26) approved orders » Group net sales amounted to SEK 884,088 (1,007,759) » Loss before tax amounted to SEK –15,547,283 (–18,454,211) » Loss per share (weighted average) amounted to SEK –0.51 (–0.97) Significant events during the fourth quarter » Episealer® 24 months’ clinical study results

Episurf Medical presents strategy update, new external financing and long-term operating targets

Episurf Medical (NASDAQ: EPIS B) today presents a strategy update, a new financing agreement and long-term operating targets. The company is close to launching an important and comprehensive clinical multicenter study in the US and Europe and the company has entered into early collaborative discussions regarding the US market.Episurf Medical addresses significant medical needs not currently met by the orthopaedic industry, and the company’s vision is to bring more people back to fully living life. The business implementation of this vision is to provide orthopaedic surgeons with clinically

Episurf Medical AB (publ) secures external financing of up to SEK 70 million and will issue free warrants to its existing shareholders

Episurf Medical AB (publ) ("Episurf") has signed an agreement relating to a financing of up to SEK 70 million. The capital will be used for execution of the company’s growth strategy. The transaction is carried out through the issuance of convertible notes (the “Notes”) with warrants attached (the “Warrants”) in several tranches spread over 36 months (each a ”Tranche”). Episurf will receive SEK 7 million through the first Tranche. Existing shareholders will receive free warrants to protect them against dilution. The financing is conditioned upon the shareholders' meeting resolving on a new

Year-End Report 2017, Heliospectra AB ( publ)

(GOTHENBURG, Sweden / SAN FRANCISCO, CA, February 23, 2018) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, are today presenting its Year-End Report for 2017.Financial Report October-December: · Net sales amounted to SEK 16,489 thousand (6,864)· Operating profit/loss was KSEK -7,478 (-12,468), involving a negative operating margin (neg)· Profit/loss after tax was KSEK -7,470 (-15,354) or SEK -0,21 (-0,44)  per share· Operating cash flow was KSEK -3,556 (-2,009).

EQT strengthens position as a leading investor and owner – closes eighth Equity fund at EUR 10.75 billion

· EQT VIII holds first and final close at EUR 10.75 billion hard cap (USD 13.2 billion) · Strong support for EQT’s responsible investment and ownership approach – growth, transformation and “future-proofing” of high-quality companies · Official launch of EQT VIII in September 2017 – less than six months in fundraising EQT today announces that the eighth fund within the Equity investment strategy, EQT VIII (or the “fund”), held a first and final close at its hard cap of EUR 10.75 billion. The fund officially launched in September 2017. Investor demand from both existing and new

Conditions fulfilled in Icelandic geothermal deal

· Order now binding as pre-conditions are met  · Baseload Capital provides financing to Varmaorka The key pre-conditions of Climeon's deal with Icelandic Heat power operator Varmaorka (owned by CP Energy) have been met. Delivery of the first seven modules will now begin. At the same time Baseload Capital Sweden AB has agreed to fund the first phase of the deal, enabling Climeon to focus on production and deliveryPer the agreement, first reported in August 2017, Varmaorka will buy 100 modules from Climeon, an order with a total value of more than 30 MEUR. The first phase of the order

Alimak Group: Fourth Quarter and Full Year 2017

Solid finish of a strong 2017 · Increased revenues for the Group in the quarter · EBITA margin adj. in Q4 at 13.8% · Significant contribution by the acquired companies to Group order intake and salesFourth quarter ·  Order intake increased by 111% to MSEK 1,096 (519) with organic decrease of 6% ·  Revenue increased by 76% to MSEK 1,050 (598) with organic growth of 4% ·  EBITA adj. increased to MSEK 145 (105), margin 13.8% (17.6) ·  EBITA increased to MSEK 127 (75), margin 12.1% (12.6) ·  EBIT increased to MSEK 113 (75), margin 10.8% (12.6) ·  Net profit

Invitation to Clas Ohlson Capital Markets Day 3 May 2018

Clas Ohlson invites analysts, investors and media to a Capital Markets Day in Stockholm to be held on 3 May 2018.The aim of the Capital Markets Day is to present Clas Ohlson’s updated strategy for future growth. The President and CEO Lotta Lyrå and other Clas Ohlson representatives will conduct presentations during the afternoon, providing further insights to Clas Ohlson’s strategy and business. Location: GT30, Grev Turegatan 30, Stockholm, Sweden Date and time: 3 May 2018 12:45-13:00     Registration13:00-17:00     Presentations and Q&A17:00-18:00     Refreshments

Swedbank’s Annual Report 2017 published

Swedbank’s Annual and Sustainability Report for 2017 has been published at www.swedbank.com/ir together with the bank’s Risk Management and Capital Adequacy Report 2017.Swedbank’s sustainability work is a central part of the bank’s operations and the sustainability report is thus an integral part of the Annual Report. For further information:Gabriel Francke Rodau, Head of Group Communications, phone: + 46 70 144 89 66Gregori Karamouzis, Head of Investor Relations, phone: + 46 72 740 63 38Fredrik Nilzén, Head of Group Sustainability, phone: +46 76 773 19 26 Swedbank AB (publ) is

Additional US patent to be granted regarding IntelliGel

The United States Patent and Trademark Office (USPTO) has communicated its intention to grant a new US patent in the portfolio licensed to Redwood Pharma from Broda International LLC. A new US patent will, when granted, provide enhanced patent protection in the United States for the so-called IntelliGel platform, which is used, inter alia, in the development of Redwood Pharmas RP101 product."We are very pleased that the protection of RP101, our drug for the treatment of chronic dry eye in women, and for other ophthalmological products, will be strengthened. As soon as the patent is granted,

There are no items matching the current filter
There are no more items matching the current filter
Back to top